Lumosa Therapeutics Co. Ltd.
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT " 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; L… Read more
Lumosa Therapeutics Co. Ltd. - Asset Resilience Ratio
Lumosa Therapeutics Co. Ltd. (6535) has an Asset Resilience Ratio of 37.37% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Lumosa Therapeutics Co. Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Lumosa Therapeutics Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$616.74 Million | 37.37% |
| Total Liquid Assets | NT$616.74 Million | 37.37% |
Asset Resilience Insights
- Very High Liquidity: Lumosa Therapeutics Co. Ltd. maintains exceptional liquid asset reserves at 37.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Lumosa Therapeutics Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Lumosa Therapeutics Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Lumosa Therapeutics Co. Ltd. (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Lumosa Therapeutics Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.37% | NT$616.74 Million | NT$1.65 Billion | -15.01pp |
| 2024-12-31 | 52.38% | NT$1.12 Billion | NT$2.13 Billion | +27.08pp |
| 2023-12-31 | 25.30% | NT$419.06 Million | NT$1.66 Billion | -10.11pp |
| 2022-12-31 | 35.41% | NT$667.67 Million | NT$1.89 Billion | +9.36pp |
| 2021-12-31 | 26.05% | NT$611.78 Million | NT$2.35 Billion | +5.18pp |
| 2020-12-31 | 20.86% | NT$372.26 Million | NT$1.78 Billion | -13.59pp |
| 2019-12-31 | 34.45% | NT$456.20 Million | NT$1.32 Billion | -- |